Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration. - Wikidata - wikimedia - TriplyDB

Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration.

Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration.

http://www.wikidata.org/entity/Q33353392

about

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration The Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study.Cost effectiveness of treatments for wet age-related macular degeneration.Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.Ranibizumab: a medical treatment that requires surgical administration.Decisional answer tree analysis of exudative age-related macular degeneration treatment outcomes.The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited.

P2860

Q24194251-BE980368-508D-48B5-AB32-7CF2C354C852 Q35716443-B0B9AEE0-2014-4DB6-ACA7-D260CD7B1998 Q37829731-A9CA8ABC-5846-41BD-B185-CAA018346C01 Q38094076-506DF617-DC26-486D-8C6A-76F5FA564279 Q42909974-92534367-E2E8-4E04-976A-9ECD765E8199 Q45942792-7A7BCE87-0695-4F38-B10F-F7C80D38CB36 Q53438701-BBA71D35-6FDE-4F27-BCC6-E1D6AACEA061

P2860

Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration.

http://www.wikidata.org/entity/Q33353392

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Cost-effectiveness sequential ...... -related macular degeneration.

@ast

Cost-effectiveness sequential ...... -related macular degeneration.

@en

type

label

Cost-effectiveness sequential ...... -related macular degeneration.

@ast

Cost-effectiveness sequential ...... -related macular degeneration.

@en

prefLabel

Cost-effectiveness sequential ...... -related macular degeneration.

@ast

Cost-effectiveness sequential ...... -related macular degeneration.

@en

P1433

Q33353392-1BC77033-8E9C-411F-8F64-93F2A556F5B4

P1476

Q33353392-E1927BBF-C883-4DE7-8419-5E379C0AEA8E

P2093

Q33353392-18FB2398-3FFC-40E3-B70A-6E0E654497F9

Q33353392-38C0B1EF-2409-4239-AAA4-A585B0BCDFC7

Q33353392-4107104E-EA53-4EBD-848C-5865657D1BAB

Q33353392-7C82BA01-2FC6-4DC9-9615-D4F5D7F46FBE

Q33353392-FD6FD6F4-777A-428C-B521-6555D7BEA076

Q33353392-FF9F5FF9-1610-44B1-A6A2-2B1C58DB3D9B

P2860

Q33353392-06321CBE-58BA-411D-90B1-788702A9A11E

Q33353392-10C28390-B5CC-4A35-83F4-D4ABDA187221

Q33353392-1829AD62-69B4-4A46-8D2F-8C8BFF45A651

Q33353392-1CC59E40-749E-41A6-AF6E-F186AF378E12

Q33353392-24F6113D-7C67-40FE-85CF-F1EA60D8875E

Q33353392-489CC1D2-6826-4D95-B65E-D5DD57F29551

Q33353392-5B85F35D-8DBD-4214-9BB6-3B7A66E4F912

Q33353392-5FA082A3-E2A4-46D2-B8E8-54A5B721C99D

Q33353392-69CBEC62-96A1-437A-AC40-E069203B7A64

Q33353392-8AA80A33-992B-4678-86D8-0EA0DDA8B2AB

P2888

Q33353392-46833A8C-10AC-4D42-807A-7CD4CBDB197D

P304

Q33353392-27DCCC0B-172C-4908-9711-BFEC47E0DCAE

P31

Q33353392-BDB39FC7-A27D-4A7C-AF12-530D22BAD81D

P356

Q33353392-E006C179-B2DF-46E4-B6FC-8E3F52A84C35

P433

Q33353392-6FED3E83-F9FD-423F-A846-51E98D5C5BD6

P478

Q33353392-1E72FA04-6410-40C2-B7B1-E36604FBE29B

P50

Q33353392-BAED4108-F6E2-4AD0-9C01-FDC6BBDC48A6

P577

Q33353392-8B608F82-AAF7-4BC9-A7A0-25D60B5859EE

P6179

Q33353392-2CED79C6-0A41-4F46-A420-428C3410FC49

P698

Q33353392-FFAED424-DE6C-4AB9-9CD7-56E46E9F5197

P356

S00417-008-0890-8

P1433

Graefe's Archive for Clinical and Experimental Ophthalmology

P1476

Cost-effectiveness sequential ...... e-related macular degeneration

@en

P2093

A Beresniak

http://www.w3.org/2001/XMLSchema#string

G Mimoun

http://www.w3.org/2001/XMLSchema#string

G Quentel

http://www.w3.org/2001/XMLSchema#string

S Bisot-Locard

http://www.w3.org/2001/XMLSchema#string

S Y Cohen

http://www.w3.org/2001/XMLSchema#string

T Citterio

http://www.w3.org/2001/XMLSchema#string

P2860

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness

Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review

Ranibizumab for neovascular age-related macular degeneration

[Photodynamic therapy. Minimally invasive treatment of choroidal neovascularization]

Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies.

Age-related macular degeneration: economic burden and value-based medicine analysis.

Age-related macular degeneration and blindness due to neovascular maculopathy.

QALYs: are they helpful to decision makers?

Recent developments in decision-analytic modelling for economic evaluation.

Combination therapy for the treatment of ocular neovascularization.

P2888

s00417-008-0890-8

P304

1527-1534

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00417-008-0890-8

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

246

http://www.w3.org/2001/XMLSchema#string

P50

Dominique Bremond-Gignac

P577

2008-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024886776

http://www.w3.org/2001/XMLSchema#string

P698

18642019

http://www.w3.org/2001/XMLSchema#string